Not Yet RecruitingNot Applicable

Percutaneous AngioVac Vegetation Extraction (PAVE) to Remove Right Heart Vegetations in Patients With Infective Endocarditis

30 participantsStarted 2026-04

Plain-language summary

The investigation aims to demonstrate initial safety and efficacy of the AngioVac System for the removal of vegetation in the right heart in patients with infective endocarditis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subject age ≥ 18 years
✓. Subject provides a signed and dated Informed Consent Form
✓. Subject has a diagnosis of native infective endocarditis
✓. Subject has presence of bacteremia with valvular (tricuspid or pulmonic) vegetations \> 1 cm confirmed by transesophageal echocardiogram (TEE) or transthoracic echocardiogram (TTE) with the presence of septic emboli
✓. Subject has no underlying terminal illness and subject is deemed medically eligible for interventional procedure(s) per institutional guidelines and/or clinical judgment

Exclusion criteria

✕. Subject requires debulking of vegetation on cardiac leads
✕. Subject has a prior history of ischemic/hemorrhagic stroke (within 3 months)
✕. Subject has a coagulation disorder
✕. Subject has arterial septic emboli
✕. Subject has cerebral septic embolism
✕. Subject has preoperative intubation due to ongoing hypoxemic respiratory failure
✕. Subject has fungal endocarditis
✕. Subject has atrial septal defect

What they're measuring

Rate of Clinical Success

Timeframe: 30 days post-procedure

Rate of Major Adverse Events (MAEs)

Timeframe: 48 hours post-procedure

Trial details

NCT IDNCT07282002

SponsorAngiodynamics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-11

Contact for this trial

Elizabeth Manning

3392372765 liz.manning@angiodynamics.com

View on ClinicalTrials.gov More Infective Endocarditis (IE) trials